Tesaro, which is developing drugs for chemotherapy-induced nausea and solid tumors, raised $81 million by offering 6 million shares at $13.50, the midpoint of the range of $12.00 to $15.00. Tesaro plans to list on the NASDAQ under the symbol TSRO. Citi, Morgan Stanley and Leerink Swann acted as lead managers on the deal.
